HC Wainwright Initiates Coverage On This Nanocrystals Stock

  • H.C. Wainwright initiated coverage on Clene Inc CLNN with a Buy rating and a $16 price target. 
  • Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of transition element nanocrystals for central nervous disorders, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease (PD).
  • The company's lead asset, CNM-Au8, is an oral, highly concentrated aqueous of catalytically active gold nanocrystals capable of overcoming the energetic deficit, oxidative stress, and accumulation of misfolded proteins that are common to many neurodegenerative diseases.
  • Related: Clene's CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients.
  • The analyst believes that Clene's approach presents key advantages and differentiating elements when compared to other therapies, including: 
    • Innovative mechanism of action compared to traditional small-molecule or biologic drug approaches.
    • Disease-modifying potential compared to currently approved drugs.
    • Robust portfolio of over 150 patents.
  • The data from the Phase 3 HEALEY ALS trial are expected in 3Q22, with potential NDA submission in 1H 2023.
  • Price Action: CLNN shares are up 7.78% at $4.85 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: BiotechNewsPenny StocksHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!